Us Bancorp \De\ Vir Biotechnology, Inc. Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

A detailed history of Us Bancorp \De\ transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 6,460 shares of VIR stock, worth $47,804. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,460

Previous 7,736 16.49%

Holding current value

$47,804

Previous $68,000 29.41%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$7.26 - $10.7 $9,263 - $13,653	-1,276 Reduced 16.49%	6,460 $48,000
Q2 2024 Aug 06, 2024	SELL	$7.63 - $12.66 $19,868 - $32,966	-2,604 Reduced 25.18%	7,736 $68,000
Q1 2024 May 07, 2024	SELL	$8.6 - $11.9 $9,193 - $12,721	-1,069 Reduced 9.37%	10,340 $104,000
Q4 2023 Feb 09, 2024	BUY	$7.76 - $10.29 $73,479 - $97,436	9,469 Added 488.09%	11,409 $114,000
Q3 2023 Nov 03, 2023	BUY	$9.14 - $24.62 $10,693 - $28,805	1,170 Added 151.95%	1,940 $18,000
Q2 2023 Aug 09, 2023	BUY	$23.2 - $27.29 $580 - $682	25 Added 3.36%	770 $18,000
Q1 2023 May 09, 2023	BUY	$22.26 - $30.85 $244 - $339	11 Added 1.5%	745 $17,000
Q4 2022 Feb 13, 2023	BUY	$19.96 - $28.22 $3,672 - $5,192	184 Added 33.45%	734 $18,000
Q3 2022 Oct 27, 2022	SELL	$18.26 - $31.1 $7,888 - $13,435	-432 Reduced 43.99%	550 $10,000
Q2 2022 Aug 01, 2022	BUY	$19.08 - $26.7 $11,924 - $16,687	625 Added 175.07%	982 $25,000
Q1 2022 May 11, 2022	BUY	$21.19 - $40.01 $1,398 - $2,640	66 Added 22.68%	357 $9,000
Q4 2021 Feb 11, 2022	SELL	$30.97 - $54.03 $3,840 - $6,699	-124 Reduced 29.88%	291 $12,000
Q3 2021 Nov 10, 2021	BUY	$34.9 - $54.54 $14,483 - $22,634	415 New	415 $18,000
Q1 2021 Apr 28, 2021	SELL	$26.34 - $83.07 $39,510 - $124,604	-1,500 Closed	0 $0
Q2 2020 Aug 07, 2020	BUY	$27.89 - $47.86 $41,835 - $71,790	1,500 New	1,500 $61,000

Others Institutions Holding VIR

# of Institutions

218

Shares Held

87M

Call Options Held

127K

Put Options Held

1.19M

View Full List

About Vir Biotechnology, Inc.

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $982M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

More about VIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account